Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

259
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
259
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

301
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
301
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

223
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
223
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

291
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
291
Asthma-I: Introduction01:29

Asthma-I: Introduction

3.5K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.5K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

3.3K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pulmonary exacerbations in patients with genetically confirmed PCD: a prospective observational multicentre study.

Frontiers in molecular biosciences·2026
Same author

Hypertransaminasemia Is a Marker of Severity in Children Hospitalized for Influenza.

Influenza and other respiratory viruses·2026
Same author

Clinical Features and Predictors of Severity in Children Hospitalized With Human Metapneumovirus: A Multicenter Italian Study.

The Pediatric infectious disease journal·2026
Same author

Evaluation of left intraventricular flow dynamics using the novel non-contrast HyperDoppler technique.

European heart journal. Imaging methods and practice·2026
Same author

From Vaping to Healing: Reversible E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI) in a Teenager.

Journal of paediatrics and child health·2026
Same author

Phenotyping Pediatric Long COVID: Symptom Clusters from a Longitudinal Multicenter Italian Cohort.

Children (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jan 30, 2026

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

6.5K

New Drugs for Pediatric Asthma.

Marco Maglione1,2, Marco Poeta1,2, Francesca Santamaria1,2

  • 1Department of Translational Medical Sciences, Federico II University, Naples, Italy.

Frontiers in Pediatrics
|February 1, 2019
PubMed
Summary

Emerging therapies show promise for uncontrolled pediatric asthma, including biologics and tiotropium. Further research is needed to confirm the safety and efficacy of these novel treatments in children.

Keywords:
adolescentsbiologicschildreninhaled corticosteroidsmacrolidesmuscarinic antagonistssevere asthmatherapy

More Related Videos

Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.3K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.5K

Related Experiment Videos

Last Updated: Jan 30, 2026

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

6.5K
Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.3K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.5K

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine
  • Clinical Pharmacology

Background:

  • Asthma is a prevalent chronic childhood illness, with treatment aiming for symptom control and lung function preservation.
  • Standard inhaled corticosteroid therapy is insufficient for over a third of pediatric patients, particularly adolescents, leading to worsening lung function and quality of life.
  • Omalizumab, a targeted biologic, is approved for pediatric uncontrolled asthma, highlighting the need for advanced treatment options.

Purpose of the Study:

  • To review emerging therapies for pediatric severe asthma.
  • To discuss the mechanisms and potential roles of novel treatments beyond current guidelines.
  • To identify gaps in evidence and future research directions for pediatric asthma management.

Main Methods:

  • Review of current literature on novel asthma therapies in pediatric populations.
  • Analysis of emerging biologic drugs, muscarinic antagonists, new inhaled corticosteroids, and macrolides.
  • Evaluation of available data on efficacy, safety, and specific age group applicability.

Main Results:

  • Novel biologics (dupilumab, mepolizumab, reslizumab, benralizumab) show potential for reducing exacerbations and steroid dependence in adolescents and adults, but pediatric data are limited.
  • Tiotropium demonstrates growing evidence as a maintenance treatment for children over 6 and preschool children, though large trials are pending.
  • New inhaled corticosteroids offer once-daily control, requiring long-term pediatric studies. Macrolides' role is controversial but may benefit specific subgroups.

Conclusions:

  • Several novel therapeutic strategies are emerging for pediatric uncontrolled asthma, including biologics and tiotropium.
  • While promising, available data for many new treatments are limited, especially in younger children, necessitating further targeted trials.
  • Future research must focus on specific pediatric age subgroups to establish the safety and efficacy of these advanced asthma therapies.